FDA Intensifies Scrutiny on Marketing Claims for Telehealth Weight Loss and Hormone Therapy Programs

The U.S. Food and Drug Administration (FDA) has significantly increased its focus on the marketing and promotional claims made by companies offering telehealth-based weight loss and hormone therapy programs. This heightened regulatory attention underscores the FDA's commitment to protecting public health by ensuring that medical products and services are marketed truthfully and are not misleading to consumers. The agency is particularly concerned about unsubstantiated claims, the promotion of unapproved drugs, and misbranding in the rapidly expanding telehealth sector.

Understanding the FDA's Regulatory Framework

The FDA regulates drugs, medical devices, and certain biologics under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and other related statutes. A core tenet of this regulation is that any claims made about a product's efficacy, safety, or intended use must be truthful, non-misleading, and substantiated by adequate scientific evidence. This applies not only to product labeling but also to advertising, promotional materials, and website content.

For drugs, the FDA requires pre-market approval based on rigorous clinical trials demonstrating safety and effectiveness for specific indications. Marketing a drug for an unapproved use (off-label promotion) or making unsubstantiated claims can lead to significant regulatory action. Similarly, medical devices must meet specific regulatory pathways, including pre-market notification (510(k)) or pre-market approval (PMA), depending on their risk classification.

Key Areas of FDA Concern

Unapproved Drugs and Misbranding

The FDA has consistently issued warning letters to companies marketing products as drugs without FDA approval. This includes products sold online or through telehealth platforms that claim to treat conditions like obesity or hormonal imbalances but have not undergone the necessary FDA review process. Misbranding can occur when a product's labeling or advertising is false or misleading, or if it fails to include required information.

Recent examples include the FDA's warnings regarding compounded semaglutide, a drug used for weight loss and diabetes. While pharmacies can compound drugs under specific circumstances, the FDA has clarified that certain practices, particularly those involving bulk drug substances not approved for compounding or the marketing of compounded versions as interchangeable with FDA-approved drugs, are unlawful. The agency has expressed concerns about the safety and efficacy of these compounded versions, especially when marketed with unsubstantiated claims. (Source: FDA.gov - Compounding and the FDA: Questions and Answers)

Unsubstantiated Efficacy and Safety Claims

The FDA is actively monitoring marketing materials that make broad or definitive claims about weight loss or hormone optimization without adequate scientific backing. This includes assertions like